Xella Health Raises $3.7 Million Pre-Seed to Launch Women’s Precision Health Platform

Xella Health has closed more than $3.7 million in pre-seed financing as it prepares to launch a women’s precision health platform in spring 2026. The company has reported that it is approaching a 10,000-person waitlist ahead of launch, reflecting early interest in its approach to understanding female biology across multiple stages of life and health conditions. The platform has been designed to combine multi-omic diagnostics, longitudinal health data tracked over time, and clinician-led guidance to support care across fertility, hormonal health, chronic conditions, early cancer detection, and preventative health.

Central to Xella’s model is its use of biological signals that have historically been underutilized in clinical practice. The company has emphasized its use of menstrual fluid alongside peripheral blood as a diagnostic input, with the goal of expanding the scope of insights available to women and their clinicians. According to Xella, this approach can support deeper understanding of menstrual irregularities and chronic pelvic pain, while also informing egg quality and quantity scores, miscarriage risk, perimenopause staging, hormone replacement therapy personalization, genetic predispositions for reproductive cancers, and broader indicators of whole-body ageing.

Kelly Lacob, co-founder and chief executive of Xella Health, said, “Our mission is to give women the answers and care they have always deserved.” She added, “Xella is building the infrastructure to decode female biology–getting to the root cause of conditions that uniquely, differently or disproportionately affect women, many of which suffer from an unacceptably poor standard of care today.” Lacob also highlighted the company’s care model, stating, “Every woman who comes to Xella works with a dedicated clinician-coach, supported by AI, to ensure that the complex data we analyse translates into meaningful, actionable health outcomes rather than more noise. This funding allows us to accelerate product development and prepare for our first launch.”

Xella Health was co-founded by Lacob alongside Adriana Dantas, chief operating officer, and Jesus Ching, chief technology officer. The pre-seed round was led by Precursor Ventures, with participation from Capital F, Ulu Ventures, other funds, and angel investors with backgrounds in healthcare, diagnostics, and consumer technology. Ashtan Jordan, principal at Precursor Ventures, said, “Xella is rethinking women’s health from the ground up—starting with the insight women need to make sense of their own biology over time.” He added, “The team is building with a rare combination of scientific depth, product intuition, and empathy for the lived realities of women, which is exactly what’s required to create a trusted, enduring platform in healthcare.”

The company has stated that the capital will be used to finalize product development, expand partnerships, and support its upcoming market launch.

Click here for the original news story.